Search
Wantai Biological Secures Marketing Authorization for Its Nine-Valent HPV Vaccine
2025-06-04 /
Read about 0 minute
Author：小编
Xiamen Wantai Canghai Biotechnology Co., Ltd., a fully-owned subsidiary of Wantai Biological, has received approval for the marketing of its nine-valent human papillomavirus vaccine (Escherichia coli), trademarked as Cecolin 9. Prior to this approval, the global market was exclusively dominated by Gardasil®9, a nine-valent HPV vaccine produced by Merck Sharp & Dohme. The introduction of Cecolin 9 is poised to bolster Wantai Biological's HPV vaccine portfolio, diversify its product offerings, and strengthen its competitive edge in the market. Nonetheless, the precise launch date and market performance of Cecolin 9 remain to be seen.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
